Výsledky vyhledávání

Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy

Autor: Margaret Hills, J-Y Pierga, Ian E. Smith, Alan Ashworth, Janine Salter, Peter T. Simpson, Jorge S. Reis-Filho, Alan Mackay, Tim Dexter, Susan Cleator, Kerry Fenwick, Chris Jones, Marjan Iravani, Mitch Dowsett, T. J. Powles

Publikováno v: British Journal of Cancer

We analysed the molecular genetic profiles of breast cancer samples before and after neoadjuvant chemotherapy with combination doxorubicin and cyclophosphamide (AC). DNA was obtained from microdissected frozen breast core biopsies from 44 patients be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61ae87143398fc323164e70ba70c6c53
https://doi.org/10.1038/sj.bjc.6603483

Zobrazit plný text záznamu

Bone Mineral Density and Lipid Changes During 5 Years of Follow-up in a Study of Prevention of Breast Cancer with Toremifene in Healthy, High-risk Pre- and Post-menopausal Women

Autor: T. J. Powles, Jorma Heikkinen, Leena Mattila, Mika Mustonen, B Toivola, P Korhonen, Risto Erkkola

Publikováno v: Breast Cancer Research and Treatment. 93:277-287

A double-blind, randomised, placebo-controlled pilot study was initiated to evaluate the feasibility of chemoprevention with toremifene 60 mg/day in healthy women at high risk for breast cancer. Enrolment in the study was terminated earlier than plan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43d45f9fd12cf443a53d8aac5aa3a00e
https://doi.org/10.1007/s10549-005-5701-x

Zobrazit plný text záznamu

Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival

Autor: Andreas Makris, T. J. Powles, Sue Ashley, R. Lal, S. J. Cleator

Publikováno v: Annals of Oncology. 16:267-272

Good clinical response of breast cancers to neoa uvant chemoendocrine therapy is associated with improved overall survival Background: We present extended follow-up from a prospective randomised trial evaluating the role of neoadjuvant chemoendocrine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87ad3f0d823f4e896d66020363fadada
https://doi.org/10.1093/annonc/mdi049

Zobrazit plný text záznamu

A Cancer Research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen

Publikováno v: Cancer Chemotherapy and Pharmacology. 53:341-348

Idoxifene is a novel selective oestrogen receptor modulator (SERM) which had greater binding affinity for the oestrogen receptor (ER) and reduced agonist activity compared with tamoxifen in preclinical studies. In a randomized phase II trial in 56 po

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::732c071ca26af2308c155a94950de380
https://doi.org/10.1007/s00280-003-0733-6

Zobrazit plný text záznamu

Studies of the Potential Utility of Ki67 as a Predictive Molecular Marker of Clinical Response in Primary Breast Cancer

Autor: T. J. Powles, Mitch Dowsett, Jenny C. Chang, Roger A'Hern, L. Assersohn, Andreas Makris, Janine Salter, R. K. Gregory

Publikováno v: Breast Cancer Research and Treatment. 82:113-123

Objectives were to characterise the relationship of the proliferation marker Ki67 with response to systemic treatment in early breast cancer and to assess its clinical utility, using fine needle aspirates.Hundred and six women were treated with prima

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::025dc4087b60b138c86e81396eb3feae
https://doi.org/10.1023/b:brea.0000003968.45511.3f

Zobrazit plný text záznamu

Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial

Autor: T. J. Powles, S. Eckert, K. A. Krueger, Alberto Costa, Avraham Karasik, Jane A. Cauley, Virgil Craig Jordan, Kong Wah Ng, Marc E. Lippman, S. L. Silfen, D. W. Purdie, E. L. Walls, Jan J. Stepan, J. Farrerons, Monica Morrow, Larry Norton, H. Schmitt, D. Mellstrom, D. B. Muchmore

Publikováno v: Breast Cancer Research and Treatment. 65:125-134

Raloxifene, a selective estrogen receptor modulator approved for the prevention and treatment of postmenopausal osteoporosis, has shown a significant reduction in breast cancer incidence after 3 years in this placebo-controlled, randomized clinical t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0135c8293e9d3f13c3d10afbc96721cc
https://doi.org/10.1023/a:1006478317173

Zobrazit plný text záznamu

Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma

Autor: G. J. Swansbury, Paul Mitchell, Kuan A, Stanley W. Ashley, R. L. Powles, Samar Kulkarni, T. J. Powles, Jennifer Treleaven, Radovan Saso, Jayesh Mehta

Publikováno v: British Journal of Cancer

Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years. Median duration of survival from diagnosis of MDS/AML was 10

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53cffc6ed9375b966269985ab5b2178d
https://doi.org/10.1054/bjoc.2000.1196

Zobrazit plný text záznamu

Tamoxifen for the prevention of breast cancer

Autor: B, Fisher, T J, Powles, K J, Pritchard

Publikováno v: European Journal of Cancer. 36:142-145

In 1991, my National Surgical Adjuvant Breast and Bowel Project (NSABP) colleagues and I concluded that enough biological and clinical data were available to provide justi®cation for conducting a clinical trial to evaluate the worth of tamoxifen for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62b575c6b133f6abbcc10991a8c5e33d
https://doi.org/10.1016/s0959-8049(99)00269-5

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání